29 results on '"Hyman, D.M."'
Search Results
2. Characterization of on-target adverse events caused by TRK inhibitor therapy
3. Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients
4. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
5. Clinical and molecular characterization of patients with cancer of unknown primary in the modern era
6. Oncologist use and perception of large panel next-generation tumor sequencing
7. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
8. The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer
9. Building bridges between drug development and cancer science: a tribute to José Baselga's legacy
10. P86.03 A Phase 2 Study of Erdafitinib in Patients with Advanced Solid Tumors and Fibroblast Growth Factor Receptor Gene Alterations
11. 553P Activity of trastuzumab and pertuzumab (HP) in patients with non-breast/gastroesophgeal HER2-amplified tumours: Results of the NCI-MATCH trial (EAY131) subprotocol J
12. B04 Activity of Larotrectinib in Tropomyosin Receptor Kinase Fusion Lung Cancer
13. Foreword
14. A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours
15. Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study)
16. Phase I dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumours: Updated results
17. Growth modulation index (GMI) as a comparative measure of clinical activity of larotrectinib versus prior systemic treatments in adult and pediatric TRK fusion cancer patients
18. Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer
19. Update on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer
20. A phase 1 study of selinexor (S) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced ovarian (OC) or endometrial cancers (EC)
21. 1196P - Phase I dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumours: Updated results
22. 685TiP - A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours
23. 485P - Growth modulation index (GMI) as a comparative measure of clinical activity of larotrectinib versus prior systemic treatments in adult and pediatric TRK fusion cancer patients
24. 445PD - Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer
25. 444PD - Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study)
26. 30P - Update on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer
27. 970P - A phase 1 study of selinexor (S) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced ovarian (OC) or endometrial cancers (EC)
28. Methodology for determining occluded gas contents in domal rock salt
29. Methane content of Gulf Coast domal rock salt
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.